HypertensionNCT06764121
Impact of Canadian Haskap Berry Powder on Hypertension and Acuity in Women's Health
A study testing Haskap Berry Powder in people with Hypertension and Alertness, run by University of Manitoba at 1 site in Canada.
Trial summary
Haskap berries are rich in cyanidin-3-O-glucoside (C3G), which has been shown in vitro to enhance endothelial function. Previous clinical studies suggest haskap berry supplementation may improve cognition, mood, blood pressure, and athletic performance, but research is limited. Read more about this study
- Who is it for?
- Ages 35 years and older, women only
- Conditions the study is for
- Hypertension, Alertness
- What is being tested?
- Haskap Berry Powder
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 32 participants
- Where
- 1 siteCanada
- Study dates
- 3 Apr 2025to 6 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Willing and able to provide informed consent to participate in the trial;
- Biological female who is at least 35 years of age;
- A waist circumference of at least 35 inches;
- Average systolic blood pressure between 120 and 150 mmHg;
- Average diastolic blood pressure between 75 and 100 mmHg
Who cannot join
- Biological male;
- Gluten allergies, celiac disease, or gluten intolerance;
- Allergic to berries;
- Receiving chemotherapy;
- Use of medications containing pseudoephedrine or other anti-inflammatory drugs, and the use of cyclosporine or tacrolimusin;
- Cardiovascular diseases including stroke, congestive heart failure, myocardial infarction, unstable angina pectoris, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, and transient ischemic attack within six months before screening;
Show all 13Show fewer
- Inability to consume treatment product;
- Inability to provide written informed consent;
- Any of the following visual impairments: diabetic retinopathy, age-related macular degeneration, glaucoma, or cataract;
- Risk of epileptic seizures;
- Any form of motor impairments;
- Any visual impairments, uncorrected vision problems, eye disorders, or injuries
- Any medical condition, uncontrolled systemic disease, or concurrent illness that would hinder study compliance or jeopardize the participant's safety, based on the investigator's opinion
Trial locations and contacts
1 site in 1 country.
Canada1 site
Richardson Centre for Food Technology and Research
Winnipeg, Manitoba, R3T 2N2
About this study
Official title: Impact of Haskalife(TM) Canadian Haskap Berry Powder Formulation on Hypertension and Acuity in Women's Health
Haskap berries are rich in cyanidin-3-O-glucoside (C3G), which has been shown in vitro to enhance endothelial function. Previous clinical studies suggest haskap berry supplementation may improve cognition, mood, blood pressure, and athletic performance, but research is limited. This trial aims to contribute to the growing body of evidence on the effects of haskap berry supplementation.
The trial is a 2-period, randomized, double-blinded, cross-over design lasting 16 weeks. During the first period (weeks 0-6), participants will receive either haskap berry powder or a control powder. A 4-week washout period follows (weeks 7-10), where no powder is consumed. In the second period (weeks 11-16), participants will receive the powder they did not consume in the first period.
- Conditions
- Hypertension, Alertness
- Being tested
- Haskap Berry Powder, Placebo Powder
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Haskap Berry PowderOther
The participants will consume four packets (16g) of haskap berry powder. The powder can be consumed with other food products.
Placebo PowderOther
The participants will consume four packets (24g) of placebo powder. The powder can be consumed with other food products.
| Study group | Role | What they receive |
|---|---|---|
| Haskap Powder then Control Powder | Experimental | The participants will consume the haskap powder between weeks 0 and 6. A washout period will occur between weeks 7 and 10. After the washout period, the participants will consume the control powder between weeks 11 and 16. None of the participants or investigators will know the identities of the powder or the participants' allocations. Receives: Other: Haskap Berry Powder; Other: Placebo Powder |
| Control Powder then Haskap Powder. | Experimental | The participants will consume the control powder between weeks 0 and 6. A washout period will occur between weeks 7 and 10. After the washout period, the participants will consume the haskap powder between weeks 11 and 16. None of the participants or investigators will know the identities of the powder or the participants' allocations. Receives: Other: Haskap Berry Powder; Other: Placebo Powder |
What is being measured
The primary outcome is the main question the study is designed to answer.
Systolic Blood Pressure
The participants' mean awake systolic blood pressure will be measured.
Measured: Weeks 0, 6, 11, and 16
Secondary outcomes (5)
Reaction Time
Mean reaction time to a series of visual stimuli.
Measured: Weeks 0, 6, 11, and 16
Memory
Rey Auditory Verbal Learning Test score
Measured: Weeks 0, 6, 11, and 16
Diastolic Blood Pressure
Mean awake diastolic blood pressure over 3 days
Measured: Weeks 0, 6, 11, and 16
Systolic and Diastolic Blood Pressure
Mean systolic and diastolic blood pressure measured over three days.
Measured: Weeks 0, 6, 11, and 16.
Heart Rate
Mean heart rate measured over three days.
Measured: Weeks 0, 6, 11, and 16
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jan 2025
- Study start3 Apr 2025
- Primary completion26 Mar 2026 (estimated)
- Study completion6 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by University of ManitobaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- The trial will be a 2-period randomized, double-blinded, cross-over study that will last for 16 weeks.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Manitoba
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Semone Myrie, PhD, Principal investigator, University of Manitoba
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06764121
- Sponsor's protocol ID
- HS26475 (B2024:057)
- Status last verified
- Nov 2025
- First submitted
- 2 Jan 2025
- Last updated
- 4 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Haskalife(TM) Canadian Haskap Berry Powder Formulation on Hypertension and Acuity in Women's Health
- ClinicalTrials.gov ID
- NCT06764121
- Acronym / sponsor ID
- HS26475 (B2024:057)
- Conditions
- Hypertension, Alertness
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 32 participants (actual)
- Lead sponsor
- University of ManitobaUniversity, hospital or other
- Study start
- 3 Apr 2025 (actual)
- Primary completion
- 26 Mar 2026 (estimated)
- Study completion
- 6 Aug 2026 (estimated)
- First posted
- 8 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Haskap berries are rich in cyanidin-3-O-glucoside (C3G), which has been shown in vitro to enhance endothelial function. Previous clinical studies suggest haskap berry supplementation may improve cognition, mood, blood pressure, and athletic performance, but research is limited. This trial aims to contribute to the growing body of evidence on the effects of haskap berry supplementation.
The trial is a 2-period, randomized, double-blinded, cross-over design lasting 16 weeks. During the first period (weeks 0-6), participants will receive either haskap berry powder or a control powder. A 4-week washout period follows (weeks 7-10), where no powder is consumed. In the second period (weeks 11-16), participants will receive the powder they did not consume in the first period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- The trial will be a 2-period randomized, double-blinded, cross-over study that will last for 16 weeks.
| Arm | Type | Receives |
|---|---|---|
| Haskap Powder then Control Powder | Experimental | Other: Haskap Berry Powder, Other: Placebo PowderThe participants will consume the haskap powder between weeks 0 and 6. A washout period will occur between weeks 7 and 10. After the washout period, the participants will consume the control powder between weeks 11 and 16. None of the participants or investigators will know the identities of the powder or the participants' allocations. |
| Control Powder then Haskap Powder. | Experimental | Other: Haskap Berry Powder, Other: Placebo PowderThe participants will consume the control powder between weeks 0 and 6. A washout period will occur between weeks 7 and 10. After the washout period, the participants will consume the haskap powder between weeks 11 and 16. None of the participants or investigators will know the identities of the powder or the participants' allocations. |
Who may qualify
- Ages
- 35 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Willing and able to provide informed consent to participate in the trial;
- Biological female who is at least 35 years of age;
- A waist circumference of at least 35 inches;
- Average systolic blood pressure between 120 and 150 mmHg;
- Average diastolic blood pressure between 75 and 100 mmHg
Key exclusion criteria (13 listed)
- Biological male;
- Gluten allergies, celiac disease, or gluten intolerance;
- Allergic to berries;
- Receiving chemotherapy;
- Use of medications containing pseudoephedrine or other anti-inflammatory drugs, and the use of cyclosporine or tacrolimusin;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Haskap Berry PowderThe participants will consume four packets (16g) of haskap berry powder. The powder can be consumed with other food products. | Other | Control Powder then Haskap Powder., Haskap Powder then Control Powder |
| Placebo PowderThe participants will consume four packets (24g) of placebo powder. The powder can be consumed with other food products. | Other | Control Powder then Haskap Powder., Haskap Powder then Control Powder |
Primary outcome
Systolic Blood Pressure
Time frame: Weeks 0, 6, 11, and 16
The participants' mean awake systolic blood pressure will be measured.
5 secondary outcomes
Reaction Time
Time frame: Weeks 0, 6, 11, and 16
Memory
Time frame: Weeks 0, 6, 11, and 16
Diastolic Blood Pressure
Time frame: Weeks 0, 6, 11, and 16
Systolic and Diastolic Blood Pressure
Time frame: Weeks 0, 6, 11, and 16.
Heart Rate
Time frame: Weeks 0, 6, 11, and 16
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Semone Myrie, PhD principal investigator
University of Manitoba
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Haskap Berry Powder in people with Hypertension and Alertness, run by University of Manitoba at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Systolic Blood Pressure (time frame: Weeks 0, 6, 11, and 16). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2025.